The Ben Towne Center’s mission is to translate scientific discoveries into innovative therapies that cure childhood cancer with minimal side effects and improve survivors’ quality of life.
We are spearheading treatments that use the immune system to eliminate cancer, without chemotherapy or radiation. Our goal is to render today’s therapies obsolete until treating childhood cancer is no different than treating an everyday virus.
Our clinical trials are helping children with acute lymphoblastic leukemia achieve complete remission.
You are helping us create a future where pediatric cancer treatment is less toxic and far less harmful
Dr. Julie Park is leading one of the world’s first clinical studies of immunotherapy for neuroblastoma – the deadliest childhood cancer.
You can help bring an end to childhood cancer all over the world, by supporting our Strong Against Cancer fundraising initiative.
Our researchers have started the first round of clinical trials exploring a potential cure.
Help us answer questions about childhood health and illness, and help other children in the future. Learn more.
Developing groundbreaking cancer treatments takes more than just the right ideas. It also takes the right people.
Please visit Seattle Children’s careers page to learn about current openings.
For information about potential opportunities in the Ben Towne Center, email us.
At Seattle Children’s, another piece of ambitious CAR-T plan in place – XconomyThe researchers and doctors at Seattle Children’s are embarking upon a complicated quest, involving multiple clinical studies of cutting-edge CAR-T cell therapies, to help kids and young adults with an aggressive form of leukemia. Seattle Children’s study, which could treat as many as 33 kids and young adults, is the first in the U.S. and part of a multi-trial scheme to explore several methods of fighting back against pediatric leukemia that anti-CD19 CAR-T alone couldn’t vanquish. “We’re thrilled that PLAT-02 has gotten so many patients into remission,” says Seattle Children’s Dr. Rebecca Gardner, who is the lead investigator for PLAT-05. “We want them to get into remission and stay in remission.”
Seattle Children’s opens trial for children and young adults with leukemia that targets CD22 and CD19 proteins simultaneously – The ASCO Post Seattle Children’s opened the first CAR T-cell immunotherapy trial in the U.S. for children and young adults with relapsed or refractory CD19- and CD22-positive acute lymphoblastic leukemia that will simultaneously attack two targets on cancer cells. Researchers hope the new experimental therapy, first being investigated in the phase 1 Pediatric Leukemia Adoptive Therapy (PLAT-05) trial, will ultimately be able to cut the rate of relapse following CAR T-cell therapy by almost half. Dr. Rebecca Gardner, an oncologist at Seattle Children’s and lead investigator for the PLAT-05 trial, and the research team, led by Dr. Mike Jensen at the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute, are launching PLAT-05 based on what they learned from their previous CAR T-cell immunotherapy trials.
Immunotherapy drug proven remarkably successful against serious stem cell transplant complication – Futurism Graft-versus-host disease (GvHD) is a serious and sometimes life-threatening disease that can arise after a stem cell transplant. Saving lives and advancing stem cell research, one new trial shows how an immunotherapy drug is drastically effective against GvHD. Dr. Leslie Kean, the trial’s principal investigator and associate director of the Ben Towne Center for Childhood Cancer Research at Seattle Children’s, said that “Given the serious threat of graft-versus-host disease, new approaches to make stem cell transplants safer for patients remain a critical unmet need. To see such striking results in patients at extremely high risk for graft-versus-disease is incredibly encouraging.”
Email the BTCCCR
1100 Olive Way, Suite 100
Seattle, WA 98101
PO Box 5371
Seattle, WA 98145-5005